SCHEMBL1285220

SCHEMBL1285220

COC(=O)c1ccc2cc(N3CCCC3)ccc2c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.56
RAB9A P51151 5/20 0.56
NPC1 O15118 5/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
NPSR1 Q6W5P4 2/20 0.56
KDM4E B2RXH2 1/20 0.56
MAPT P10636 6/20 0.52
KMT2A Q03164 4/20 0.52
MCL1 Q07820 2/20 0.52
MEN1 O00255 2/20 0.52
POLB P06746 1/20 0.52
NR4A1 P22736 1/20 0.50
PTPN11 Q06124 1/20 0.49
HDAC6 Q9UBN7 1/20 0.47
USP2 O75604 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
LCK P06239 1/20 0.47
TSHR P16473 2/20 0.46
ABL1 P00519 2/20 0.46
ALOX15 P16050 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30893008 1.00 ALDH1A1 (0.56) ALDH1A1RAB9ANPC1SMN1; SMN2NPSR1
SCHEMBL20220824 0.98 RAB9A (0.58) ALDH1A1RAB9ANPC1SMN1; SMN2NPSR1
SCHEMBL1285085 0.98 RAB9A (0.58) ALDH1A1RAB9ANPC1SMN1; SMN2NPSR1
SCHEMBL30343614 0.98 RAB9A (0.58) ALDH1A1RAB9ANPC1SMN1; SMN2NPSR1
SCHEMBL1286077 0.97 ALDH1A1 (0.56) ALDH1A1RAB9ANPC1SMN1; SMN2NPSR1
SCHEMBL1645102 0.87 MRGPRX4 (0.60) ALDH1A1RAB9ANPC1SMN1; SMN2NPSR1
SCHEMBL2951325 0.84 ALDH1A1 (0.71) ALDH1A1RAB9ANPC1SMN1; SMN2NPSR1
SCHEMBL15681648 0.83 SIRT2 (0.59) ALDH1A1RAB9ANPC1SMN1; SMN2MAPT
SCHEMBL17640683 0.83 MAPT (0.52) ALDH1A1RAB9ANPC1SMN1; SMN2NPSR1
SCHEMBL5742108 0.82 ALDH1A1 (0.69) ALDH1A1RAB9ANPC1SMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240325572-A1 N-HETEROCYCLYL SUBSTITUTED 2-CYANO-3-(NAPHTHALEN-2-YL)ACRYLAMIDE DERIVATIVES AS FLUOROPHORS FOR DETECTION OF AMYLOID AND AMYLOID-LIKE PROTEINS FOR DIAGNOSIS OF NEURODEGENERATIVE DISORDERS Amydis, Inc. 2024-10-03 US disclosed
CN-117916225-A N-heterocyclyl substituted 2-cyano-3- (naphthalen-2-yl) acrylamide derivatives as fluorophores for detection of amyloid and amyloid-like proteins for diagnosis of neurodegenerative disorders 阿米达斯公司 2024-04-19 CN disclosed
WO-2023288109-A1 N-HETEROCYCLYL SUBSTITUTED 2-CYANO-3-(NAPHTHALEN-2-YL)ACRYLAMIDE DERIVATIVES AS FLUOROPHORS FOR DETECTION OF AMYLOID AND AMYLOID-LIKE PROTEINS FOR DIAGNOSIS OF NEURODEGENERATIVE DISORDERS Amydis, Inc. (US) 2023-01-19 WO disclosed
US-20120088746-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME PFIZER INC. (US) 2012-04-12 US disclosed
US-20120088746-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME PFIZER INC. (US) 2012-04-12 US disclosed
US-20120088746-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME PFIZER INC. (US) 2012-04-12 US disclosed
EP-2024272-A2 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME Renovis, Inc. (US) 2009-02-18 EP disclosed
WO-2007133637-A2 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME RENOVIS, INC. (US) 2007-11-22 WO disclosed
WO-2007133637-A2 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME RENOVIS, INC. (US) 2007-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088746-A1 AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME TRPV1, TRPA1, TRPV2 ALDH1A1 1265/4885RAB9A 2452/4885NPC1 879/4885
US-20240325572-A1 N-HETEROCYCLYL SUBSTITUTED 2-CYANO-3-(NAPHTHALEN-2-YL)ACRYLAMIDE DERIVATIVES AS FLUOROPHORS FOR DETECTION OF AMYLOID AND AMYLOID-LIKE PROTEINS FOR DIAGNOSIS OF NEURODEGENERATIVE DISORDERS TARDBP, CDR2, NLN ALDH1A1 2727/4885RAB9A 3012/4885NPC1 1230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.